Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.

Wang L, Yang H, Zamperone A, Diolaiti D, Palmbos PL, Abel EV, Purohit V, Dolgalev I, Rhim AD, Ljungman M, Hadju CH, Halbrook CJ, Bar-Sagi D, di Magliano MP, Crawford HC, Simeone DM.

Genes Dev. 2019 Jun 1;33(11-12):641-655. doi: 10.1101/gad.323303.118. Epub 2019 May 2.

PMID:
31048544
2.

A surgical orthotopic approach for studying the invasive progression of human bladder cancer.

Lorenzatti Hiles G, Cates AL, El-Sawy L, Day KC, Broses LJ, Han AL, Briggs HL, Emamdjomeh A, Chou A, Abel EV, Liebert M, Palmbos PL, Udager AM, Keller ET, Day ML.

Nat Protoc. 2019 Mar;14(3):738-755. doi: 10.1038/s41596-018-0112-8.

3.

ATDC mediates a TP63-regulated basal cancer invasive program.

Palmbos PL, Wang Y, Bankhead Iii A, Kelleher AJ, Wang L, Yang H, Ahmet ML, Gumkowski ER, Welling SD, Magnuson B, Leflein J, Lorenzatti Hiles G, Abel EV, Dziubinski ML, Urs S, Day ML, Ljungman ME, Simeone DM.

Oncogene. 2019 May;38(18):3340-3354. doi: 10.1038/s41388-018-0646-9. Epub 2019 Jan 14.

4.

HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties.

Abel EV, Goto M, Magnuson B, Abraham S, Ramanathan N, Hotaling E, Alaniz AA, Kumar-Sinha C, Dziubinski ML, Urs S, Wang L, Shi J, Waghray M, Ljungman M, Crawford HC, Simeone DM.

Elife. 2018 Aug 3;7. pii: e33947. doi: 10.7554/eLife.33947.

5.

GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer.

Waghray M, Yalamanchili M, Dziubinski M, Zeinali M, Erkkinen M, Yang H, Schradle KA, Urs S, Pasca Di Magliano M, Welling TH, Palmbos PL, Abel EV, Sahai V, Nagrath S, Wang L, Simeone DM.

Cancer Discov. 2016 Aug;6(8):886-99. doi: 10.1158/2159-8290.CD-15-0947. Epub 2016 May 16.

6.

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS.

Oncogene. 2016 Mar 10;35(10):1225-35. doi: 10.1038/onc.2015.188. Epub 2015 Jun 15.

7.

ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis.

Wang L, Yang H, Abel EV, Ney GM, Palmbos PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, Wilkinson JE, Prasad J, Ljungman M, Rhim AD, Pasca di Magliano M, Simeone DM.

Genes Dev. 2015 Jan 15;29(2):171-83. doi: 10.1101/gad.253591.114.

8.

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.

Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM.

Clin Cancer Res. 2014 Dec 1;20(23):5937-5945. doi: 10.1158/1078-0432.CCR-14-1269. Epub 2014 Oct 2.

9.

FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma.

Weiss MB, Abel EV, Dadpey N, Aplin AE.

Mol Cancer Res. 2014 Sep;12(9):1314-23. doi: 10.1158/1541-7786.MCR-14-0170. Epub 2014 Jul 24.

10.

The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer.

Abel EV, Kim EJ, Wu J, Hynes M, Bednar F, Proctor E, Wang L, Dziubinski ML, Simeone DM.

PLoS One. 2014 Mar 19;9(3):e91983. doi: 10.1371/journal.pone.0091983. eCollection 2014.

11.

In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE.

Cancer Res. 2013 Dec 1;73(23):7101-10. doi: 10.1158/0008-5472.CAN-13-1628. Epub 2013 Oct 11.

12.

SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells.

Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA, Gomez TS, Simeone DM, Bujanda L, Billadeau DD.

Oncogenesis. 2013 Aug 5;2:e61. doi: 10.1038/oncsis.2013.23.

13.

Biology and clinical applications of pancreatic cancer stem cells.

Abel EV, Simeone DM.

Gastroenterology. 2013 Jun;144(6):1241-8. doi: 10.1053/j.gastro.2013.01.072. Review.

PMID:
23622133
14.

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE.

J Clin Invest. 2013 May;123(5):2155-68. doi: 10.1172/JCI65780. Epub 2013 Apr 1.

15.

TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells.

Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE.

Cancer Res. 2012 Dec 15;72(24):6382-92. doi: 10.1158/0008-5472.CAN-12-1033. Epub 2012 Dec 7.

16.

SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

Kaplan FM, Kugel CH 3rd, Dadpey N, Shao Y, Abel EV, Aplin AE.

J Biol Chem. 2012 Dec 7;287(50):41797-807. doi: 10.1074/jbc.M112.390906. Epub 2012 Oct 17.

17.

GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation.

John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS.

J Invest Dermatol. 2012 Dec;132(12):2818-27. doi: 10.1038/jid.2012.237. Epub 2012 Jul 19.

18.

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.

Basile KJ, Abel EV, Aplin AE.

Oncogene. 2012 May 10;31(19):2471-9. doi: 10.1038/onc.2011.424. Epub 2011 Sep 26.

19.

A homing endonuclease and the 50-nt ribosomal bypass sequence of phage T4 constitute a mobile DNA cassette.

Bonocora RP, Zeng Q, Abel EV, Shub DA.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16351-6. doi: 10.1073/pnas.1107633108. Epub 2011 Sep 19.

20.

Finding the root of the problem: the quest to identify melanoma stem cells.

Abel EV, Aplin AE.

Front Biosci (Schol Ed). 2011 Jun 1;3:937-45. Review.

21.

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS.

Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11.

22.

FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Abel EV, Aplin AE.

Cancer Res. 2010 Apr 1;70(7):2891-900. doi: 10.1158/0008-5472.CAN-09-3139. Epub 2010 Mar 23.

23.

Mcl-1 is required for melanoma cell resistance to anoikis.

Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE.

Mol Cancer Res. 2009 Apr;7(4):549-56. doi: 10.1158/1541-7786.MCR-08-0358.

24.

B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization.

Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE.

Mol Biol Cell. 2008 Feb;19(2):498-508. Epub 2007 Nov 28.

25.

Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.

Spofford LS, Abel EV, Boisvert-Adamo K, Aplin AE.

J Biol Chem. 2006 Sep 1;281(35):25644-51. Epub 2006 Jun 29.

Supplemental Content

Support Center